Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib. Wang XV, Hanson CA, Tschumper RC, Lesnick CE, et al. Blood 2021;138:2810-2827.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Wang XV, Hanson CA, Tschumper RC, Lesnick CE, et al. Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib. Blood 2021;138:2810-2827.
PMID: 34407545